GO:1900077 negative regulation of cellular response to insulin stimulus: Signaling Brake, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900077 describes any process that stops, prevents, or reduces the cellular response to insulin, acting as a negative feedback brake on insulin signaling.
• Immediate-early transcriptional programs downstream of insulin receptor stimulation include genes that feed back to dampen the response, such as transcriptional repressors and RNA-binding proteins.
• Key negative regulators include TRPM4, which limits calcium-dependent insulin granule exocytosis, and microRNA-9, which represses Granuphilin/Slp4 and the secretory response.
• Dysregulation of this term contributes to beta-cell failure in type 2 diabetes, glucotoxicity, and obesity-related immune dysfunction.
• REL A (NF-kB p65) governs islet-specific metabolic gene networks and can modulate insulin response pathways.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of negative regulators in insulin response.
Description
The Gene Ontology term GO:1900077, negative regulation of cellular response to insulin stimulus, captures any biological process that stops, prevents, or reduces the frequency, rate, or extent of the cellular response to insulin. Insulin is a master metabolic hormone, and its cellular response must be tightly controlled to avoid excessive or prolonged signaling, which can lead to insulin resistance, beta-cell exhaustion, and metabolic disease. This term is therefore central to understanding feedback loops that maintain metabolic homeostasis. Researchers studying diabetes, obesity, and insulin-secreting cells need to identify the genes and mechanisms that execute this negative regulation. For example, immediate-early transcriptional responses to insulin receptor stimulation include feedback inhibitors that shape the duration and intensity of signaling. Additionally, proteins such as TRPM4 control insulin secretion by modulating calcium influx, thereby acting as negative regulators of the secretory response. MicroRNA-9 represses Granuphilin/Slp4, a protein required for insulin granule exocytosis, providing another layer of negative control. Understanding GO:1900077 is thus essential for mapping the molecular brakes on insulin action and for developing therapeutic strategies that restore proper regulation in disease.
negative regulation of cellular response to insulin stimulus At A Glance
| GO ID | GO:1900077 |
|---|---|
| GO term | negative regulation of cellular response to insulin stimulus |
| Ontology | biological_process |
| Synonym | down regulation of cellular response to insulin stimulus, down-regulation of cellular response to insulin stimulus, downregulation of cellular response to insulin stimulus, inhibition of cellular response to insulin stimulus |
| Major function | Dampening or terminating cellular signaling and metabolic responses triggered by insulin |
| Related processes | Insulin secretion, glucose uptake, gene expression, vesicle trafficking |
| Cellular context | Insulin-responsive tissues such as pancreatic beta-cells, adipocytes, skeletal muscle, and liver |
| Disease relevance | Type 2 diabetes, obesity, insulin resistance, beta-cell dysfunction |
What Is GO:1900077?
GO:1900077 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of cellular response to insulin stimulus. In other words, it encompasses molecular events that put the brakes on how a cell reacts to insulin, ensuring that the response is not excessive or prolonged. This can occur through transcriptional repression, post-transcriptional regulation, protein degradation, or modulation of signaling intermediates.
Why Is negative regulation of cellular response to insulin stimulus Important in Cell Biology?
GO:1900077 is critical because unrestrained insulin signaling can lead to pathological outcomes such as insulin resistance, hyperinsulinemia, and beta-cell failure. Negative regulation ensures that insulin responses are transient and appropriate, preventing cellular overstimulation. In pancreatic beta-cells, negative regulators like TRPM4 and microRNA-9 control insulin granule exocytosis, and their dysregulation contributes to impaired insulin secretion in type 2 diabetes. In obesity, chronic low-grade inflammation and metabolic stress can alter negative feedback mechanisms, as seen in NK cells from children with obesity. Moreover, transcriptional regulators such as RELA (NF-kB p65) govern islet-specific metabolic gene networks that intersect with insulin response pathways. Thus, understanding this term provides insights into disease mechanisms and potential therapeutic targets.
• Prevents excessive insulin signaling that could lead to insulin resistance.
• Controls insulin granule exocytosis in beta-cells to avoid hypersecretion.
• Modulates calcium signaling through TRPM4 to fine-tune insulin secretion.
• Regulates immediate-early gene expression downstream of insulin receptor activation.
• Influences adipocyte differentiation and metabolic gene expression.
• Contributes to beta-cell failure under glucotoxic conditions in type 2 diabetes.
• Affects immune cell function in obesity, linking metabolism to inflammation.
• Provides targets for therapeutic intervention to restore insulin sensitivity.
• Helps explain inter-individual variability in insulin response and diabetes risk.
• Essential for interpreting CRISPR screens aimed at identifying insulin signaling modulators.
What Happens During negative regulation of cellular response to insulin stimulus?
Transcriptional feedback and immediate-early gene induction
In simple terms: When insulin activates its receptor, the cell turns on genes that later put the brakes on the same pathway.
Insulin receptor stimulation triggers a rapid transcriptional program that includes immediate-early genes, some of which encode negative regulators of the insulin response. This feedback loop ensures that the cellular response is self-limiting. For example, insulin-induced transcription factors can repress genes involved in glucose uptake or insulin secretion, thereby reducing the overall response. The precise set of immediate-early genes varies by cell type but often includes transcriptional repressors and RNA-binding proteins that destabilize mRNAs encoding positive regulators.
Post-transcriptional regulation by RNA-binding proteins and microRNAs
In simple terms: Small RNAs and RNA-binding proteins can degrade or block the messages needed for insulin action.
MicroRNA-9 controls the expression of Granuphilin/Slp4, a protein essential for insulin granule exocytosis, thereby negatively regulating the secretory response of insulin-producing cells. Similarly, the RNA-binding protein tristetraprolin (TTP) is regulated during adipocyte differentiation and can destabilize mRNAs encoding proteins involved in insulin signaling, contributing to negative feedback. These post-transcriptional mechanisms allow rapid and reversible dampening of the insulin response without new transcription.
Ion channel modulation and calcium signaling
In simple terms: Ion channels like TRPM4 can reduce calcium entry, which is needed for insulin release.
TRPM4 is a calcium-activated non-selective cation channel that controls insulin secretion in pancreatic beta-cells. Activation of TRPM4 leads to membrane depolarization and reduced calcium influx, thereby limiting insulin granule exocytosis. This represents a direct negative regulation of the cellular response to insulin stimulus at the level of secretion. Other ion channels and transporters may similarly modulate the response by altering membrane potential or calcium handling.
Vesicle trafficking and exocytosis machinery
In simple terms: Proteins that control how insulin granules fuse with the cell membrane can be inhibited to reduce secretion.
The exocytosis of insulin granules requires SNARE proteins, small GTPases, and cytoskeletal remodeling. Negative regulation can occur through the inhibition or degradation of these components. For instance, Granuphilin/Slp4 is a negative regulator of insulin exocytosis, and its downregulation by microRNA-9 enhances secretion, while its overexpression reduces it. Thus, the trafficking machinery is a key node for negative control of the insulin response.
Cross-talk with inflammatory and stress signaling pathways
In simple terms: Inflammation and cellular stress can activate pathways that block insulin action.
In obesity, chronic inflammation and metabolic stress activate signaling cascades that interfere with insulin signaling. For example, NK cells from children with obesity are metabolically stressed and functionally deficient, suggesting that stress pathways can negatively regulate insulin responsiveness in immune cells. Additionally, the transcription factor RELA (NF-kB p65) governs a network of islet-specific metabolic genes necessary for beta cell function, and its dysregulation may contribute to negative regulation of insulin response under inflammatory conditions. These cross-talk mechanisms link GO:1900077 to broader physiological states.
Key Genes Involved in GO:1900077 negative regulation of cellular response to insulin stimulus
The following genes and proteins have been experimentally implicated in negative regulation of the cellular response to insulin stimulus, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TRPM4 | Calcium-activated cation channel that limits insulin secretion | Negative regulator of insulin granule exocytosis; target for modulating beta-cell function |
| miR-9 | MicroRNA that represses Granuphilin/Slp4 | Controls secretory response of insulin-producing cells; potential therapeutic target |
| Granuphilin/Slp4 | Rab effector involved in insulin granule docking | Its downregulation enhances secretion; negative regulator of exocytosis |
| TTP (ZFP36) | RNA-binding protein that destabilizes mRNAs | Regulated during adipocyte differentiation; may dampen insulin signaling |
| RELA (NF-kB p65) | Transcription factor governing islet metabolic genes | Modulates beta-cell function and insulin response networks |
| INSR | Insulin receptor; initiates signaling | Its downregulation or desensitization is a form of negative regulation |
| IRS1/2 | Insulin receptor substrates | Their degradation or phosphorylation at inhibitory sites reduces insulin signaling |
| PIK3R1 | Regulatory subunit of PI3K | Can act as a negative regulator when overexpressed or modified |
| PTEN | Lipid phosphatase that opposes PI3K | Negative regulator of insulin signaling; often studied in insulin resistance |
| PTP1B (PTPN1) | Protein tyrosine phosphatase | Dephosphorylates insulin receptor, terminating signaling |
| SOCS1/3 | Suppressors of cytokine signaling | Inhibited by inflammatory signals; negatively regulate insulin signaling |
| FOXO1 | Transcription factor | Can feedback to reduce insulin sensitivity; regulated by insulin |
| SIRT1 | NAD-dependent deacetylase | Modulates insulin sensitivity and negative feedback |
| AMPK | Energy sensor kinase | Can inhibit insulin signaling under energy stress |
| mTORC1 | Nutrient-sensing kinase | Hyperactivation leads to negative feedback on insulin signaling |
| GRB10 | Adaptor protein | Negatively regulates insulin receptor signaling |
| PDE3B | Phosphodiesterase | Degrades cAMP, modulating insulin secretion |
| RAB27A | Small GTPase | Involved in insulin granule exocytosis; its regulation affects secretion |
How Is negative regulation of cellular response to insulin stimulus Regulated?
The process of negative regulation of cellular response to insulin stimulus is itself tightly regulated. Immediate-early transcriptional responses to insulin receptor stimulation induce feedback inhibitors that shut down the pathway. Post-transcriptional mechanisms, such as microRNA-9-mediated repression of Granuphilin/Slp4, provide rapid tuning of the secretory response. Ion channels like TRPM4 modulate calcium signaling to limit exocytosis. Additionally, inflammatory and stress pathways, including NF-kB signaling via RELA, can intersect with insulin signaling to negatively regulate it. Metabolic sensors such as AMPK and mTORC1 also play roles in feedback regulation under conditions of energy excess or nutrient stress.
negative regulation of cellular response to insulin stimulus and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TRPM4 | Type 2 diabetes, insulin secretion defects | Beta-cell-specific knockout or overexpression in mice |
| miR-9 | Beta-cell dysfunction, impaired insulin secretion | miR-9 knockout or transgenic mice; CRISPR knockout in INS-1 cells |
| RELA | Beta-cell failure, inflammation-induced insulin resistance | Conditional knockout in pancreatic islets |
| PTPN1 (PTP1B) | Insulin resistance, obesity | Liver-specific knockout or pharmacological inhibition |
| ZFP36 (TTP) | Adipocyte dysfunction, metabolic syndrome | Adipose-specific knockout or knock-in of phospho-mutants |
Type 2 diabetes and beta-cell failure
In type 2 diabetes, chronic hyperglycemia and hyperlipidemia (glucotoxicity and lipotoxicity) impair beta-cell function and contribute to beta-cell failure. Negative regulation of insulin response becomes maladaptive when it excessively suppresses insulin secretion or promotes insulin resistance. For example, overexpression of microRNA-9 or TRPM4 can reduce insulin secretion, exacerbating hyperglycemia. Conversely, loss of negative feedback can lead to beta-cell exhaustion. Thus, GO:1900077 is central to understanding the balance between adequate insulin secretion and beta-cell protection.
Obesity and metabolic inflammation
Obesity is associated with chronic low-grade inflammation that can alter insulin responsiveness in various tissues. NK cells from children with obesity are activated, metabolically stressed, and functionally deficient, indicating that immune cells also undergo negative regulation of insulin response under obese conditions. Inflammatory cytokines activate NF-kB (RELA), which can interfere with insulin signaling and contribute to insulin resistance. Therefore, negative regulation of insulin response is a key node linking obesity, inflammation, and metabolic disease.
Insulin resistance in peripheral tissues
Insulin resistance in skeletal muscle, liver, and adipose tissue involves impaired insulin signaling due to increased activity of negative regulators such as PTP1B, PTEN, and SOCS proteins. These phosphatases and suppressors dephosphorylate or inhibit key signaling intermediates, effectively stopping the cellular response to insulin. Understanding how these negative regulators are controlled may lead to new therapies for insulin resistance.
From negative regulation of cellular response to insulin stimulus-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate insulin secretion? | CRISPR knockout of gene X in pancreatic beta-cell lines (e.g., INS-1, MIN6) followed by insulin secretion assays |
| Does a specific point mutation in gene Y alter its negative regulatory function? | CRISPR point mutation knock-in in beta-cells or adipocytes |
| Does overexpression of gene Z suppress insulin response? | CRISPR activation (CRISPRa) or lentiviral overexpression in insulin-responsive cells |
| Does tagging of protein W affect its localization and function? | CRISPR knock-in of fluorescent or epitope tags |
| Which genes are essential for negative feedback? | Genome-wide CRISPR knockout library screening in insulin-responsive cells |
| How does a disease-associated SNP affect negative regulation? | CRISPR knock-in of the SNP in isogenic cell lines |
How to Study the negative regulation of cellular response to insulin stimulus Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript changes | Identify immediate-early genes and negative feedback regulators |
| Insulin secretion assay (ELISA) | Amount of insulin released | Assess negative regulation of exocytosis |
| Western blot | Phosphorylation of signaling proteins | Measure insulin signaling intensity and duration |
| CRISPR knockout screening | Gene essentiality for insulin response | Discover novel negative regulators |
| Phosphoproteomics | Site-specific phosphorylation changes | Map signaling nodes and feedback loops |
| Live-cell imaging | Granule trafficking and exocytosis | Visualize negative regulation of secretion |
| qRT-PCR | Expression of specific genes/miRNAs | Validate microRNA-9 and target genes |
| Glucose uptake assay | Cellular glucose transport | Measure insulin sensitivity in adipocytes/muscle |
Transcriptomic profiling of immediate-early responses
RNA-seq and microarray analysis can identify genes induced or repressed immediately after insulin receptor stimulation, revealing negative feedback regulators. Time-course experiments are essential to capture immediate-early transcriptional changes. This approach has been used to map the transcriptional response to insulin in various cell types.
Functional assays for insulin secretion and signaling
Insulin secretion assays (ELISA), glucose uptake assays, and Western blotting for phosphorylated signaling intermediates (e.g., AKT, ERK) are standard methods to measure the cellular response to insulin and its negative regulation. These assays can be combined with genetic perturbations to test causality.
CRISPR screening for negative regulators
Genome-wide CRISPR knockout or activation screens in insulin-responsive cells can identify genes whose loss or gain alters insulin response. Such screens have been instrumental in uncovering negative regulators of signaling pathways. Hits can be validated individually using targeted CRISPR models.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation after insulin stimulation, revealing negative feedback nodes. This is particularly useful for identifying phosphatases and kinases that terminate signaling.
How CRISPR Can Be Used to Study GO:1900077 negative regulation of cellular response to insulin stimulus
Knockout
CRISPR knockout of candidate negative regulators (e.g., TRPM4, miR-9 host gene) in beta-cell lines or primary islets can test whether their loss enhances insulin secretion or signaling. Knockout models are essential for establishing causality.
Point Mutation
Introducing specific point mutations (e.g., in TRPM4 channel pore or phosphorylation sites of IRS1) via CRISPR can dissect domain-specific functions in negative regulation. This is crucial for understanding how post-translational modifications affect feedback.
Knock-in
Knock-in of reporter tags (e.g., GFP) or disease-associated SNPs into endogenous loci allows real-time tracking of protein localization and function, and assessment of how genetic variants alter negative regulation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of negative regulators can suppress insulin response, mimicking pathological states such as beta-cell dysfunction. Overexpression models help identify dose-dependent effects.
How EDITGENE Supports negative regulation of cellular response to insulin stimulus Research
Researchers studying negative regulation of cellular response to insulin stimulus-related genes often need to determine whether a candidate gene is causally involved in dampening insulin signaling or secretion. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cellular response to insulin stimulus research.
Frequently Asked Questions About negative regulation of cellular response to insulin stimulus
What is GO:1900077?
GO:1900077 is the Gene Ontology term for negative regulation of cellular response to insulin stimulus, describing any process that stops, prevents, or reduces the cellular response to insulin.
What genes are involved in negative regulation of insulin response?
Key genes include TRPM4, microRNA-9, Granuphilin/Slp4, ZFP36 (TTP), RELA, PTPN1, and PTEN, among others.
How does microRNA-9 negatively regulate insulin secretion?
MicroRNA-9 represses the expression of Granuphilin/Slp4, a protein required for insulin granule exocytosis, thereby reducing the secretory response.
What is the role of TRPM4 in insulin secretion?
TRPM4 is a calcium-activated cation channel that limits calcium influx and insulin granule exocytosis, acting as a negative regulator of insulin secretion.
How is negative regulation of insulin response linked to type 2 diabetes?
In type 2 diabetes, excessive or dysregulated negative regulation can impair insulin secretion and contribute to beta-cell failure, while loss of feedback can cause insulin resistance.
What experimental models are used to study GO:1900077?
Common models include CRISPR knockout and knock-in in beta-cell lines, primary islets, and animal models, combined with insulin secretion assays and transcriptomics.
Can CRISPR screening identify new negative regulators of insulin signaling?
Yes, genome-wide CRISPR knockout or activation screens in insulin-responsive cells can uncover novel genes that negatively regulate the insulin response.
What is the difference between negative regulation of insulin response and insulin resistance?
Negative regulation is a normal physiological feedback mechanism, while insulin resistance is a pathological state where cells fail to respond to insulin, often due to chronic negative regulation or signaling defects.
Which transcription factors mediate negative feedback in insulin signaling?
Immediate-early transcription factors induced by insulin, as well as RELA (NF-kB p65), can mediate negative feedback on insulin response genes.
How does obesity affect negative regulation of insulin response?
Obesity-associated inflammation and metabolic stress can alter negative regulation, as seen in functionally deficient NK cells from children with obesity, linking immune dysfunction to insulin resistance.
Conclusion
GO:1900077, negative regulation of cellular response to insulin stimulus, is a fundamental biological process that ensures appropriate and self-limiting insulin action. Dysregulation of this process contributes to major metabolic diseases, including type 2 diabetes and obesity. Understanding the genes and mechanisms involved, such as TRPM4, microRNA-9, and RELA, provides opportunities for therapeutic intervention. Advanced CRISPR tools and functional genomics approaches are indispensable for dissecting this complex regulatory network.
References
- 1. Thiel G et al.. 2021. Immediate-early transcriptional response to insulin receptor stimulation.. Biochem Pharmacol 192:114696 PMID: 34302794
- 2. Wang Z et al.. 2009. Mechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins.. J Cell Sci 122(Pt 7):893-903 PMID: 19295123
- 3. Kaiser N et al.. 2003. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus.. J Pediatr Endocrinol Metab 16(1):5-22 PMID: 12585335
- 4. Zammit NW et al.. 2023. RELA governs a network of islet-specific metabolic genes necessary for beta cell function.. Diabetologia 66(8):1516-1531 PMID: 37311878
- 5. Tobin LM et al.. 2017. NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient.. JCI Insight 2(24) PMID: 29263296
- 6. Plaisance V et al.. 2006. MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells.. J Biol Chem 281(37):26932-42 PMID: 16831872
- 7. Cheng H et al.. 2007. TRPM4 controls insulin secretion in pancreatic beta-cells.. Cell Calcium 41(1):51-61 PMID: 16806463
- 8. Lin NY et al.. 2007. Regulation of tristetraprolin during differentiation of 3T3-L1 preadipocytes.. FEBS J 274(3):867-78 PMID: 17288565
